NCT-503 NEW
| Price | $35 | $57 | $92 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-17 |
Product Details
| Product Name: NCT-503 | CAS No.: 1916571-90-8 |
| Purity: 99.56% | Supply Ability: 10g |
| Release date: 2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | NCT-503 |
| 描述 | NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=2.5 μM) with no activity against other dehydrogenases. NCT-503 has antitumor activity and inhibits the growth of PHGDH-dependent tumors. |
| 動物實驗 | Animal Models: NOD.SCID mice bearing MDA-MB-231 and MDA-MB-468 orthotropic xenograftsFormulation: 5% ethanol, 35% PEG 300, and 60% of an aqueous 30% hydroxypropyl-β-cyclodextrin solutionDosages: 40 mg/kgAdministration: i.p.(Only for Reference) |
| 體外活性 | METHODS: Mouse bone marrow cells (BMC) transformed with MLL-AF9 and Hoxa9/Meis1 (HM-2) were treated with MI-503 (0-5 μM) for 7 days, and viability was measured by MTT assay. RESULTS: Treatment of MLL-AF9 oncogene-transformed BMC with MI-503 resulted in significant growth inhibition, with a GI50 value of 0.22 μM measured after 7 days of treatment.[1] METHODS: AGS cells overexpressing wild-type menin and three mutant proteins were treated with MI-503 (1 μmol/L) for 48 h. The expression levels of target proteins were detected by Western Blot. RESULTS: MI-503 increased the expression of nuclear proteins, with the greatest effect observed in R516fs and E235K mutants. [2] |
| 體內(nèi)活性 | METHODS: To test the in vivo antitumor activity, MI-503 (60 mg/kg, 25% DMSO+25% PEG400+50% PBS) was administered intraperitoneally to BALB/c nude mice bearing MV4;11 xenografts once a day for 20 days. RESULTS: MI-503 strongly inhibited tumor growth, and treatment with MI-503 resulted in more than 80% reduction of MV4;11, and complete regression of tumor volume and tumor in two mice. [1] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 75 mg/mL (183.6 mM) DMSO : 18.33 mg/mL (44.88 mM) |
| 關(guān)鍵字 | inhibit | Inhibitor | NCT503 | NCT-503 |
| 相關(guān)產(chǎn)品 | Disulfiram | Methotrexate | Gilteritinib | Nintedanib | Rotenone | Mycophenolate Mofetil | Ribavirin | Sorafenib | Benzyl alcohol | Isomalt | Sodium Oxamate | Ivosidenib |
| 相關(guān)庫 | 高選擇性抑制劑庫 | 抗肺癌化合物庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 激酶抑制劑庫 | 抗癌細(xì)胞代謝庫 | 抑制劑庫 | 代謝化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY